PBYI PUMA BIOTECHNOLOGY INC
Health Care · Russell 2000
Next earnings: not announced yet
What 3 analyst firms say about PUMA BIOTECHNOLOGY INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
2 rated views · 3 analyst/firm records · 3 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 5 analysts in the last 6 months (3)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 5 analysts in the last 6 months (3)
Recent analyst activity · last 90 days
Our tracked history has 1 report on PBYI from 1 analyst firm in the last 90 days (3 firms in the past year).
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| TD Cowen | Marc Frahm | Hold | 7 Aug 2026 | 6.00 USD |
| Weiss Ratings | Unnamed analyst | — | 8 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | Conflicting reports · excluded |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:16 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.